A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504673-20-00

Acronym

77242113UCO2001

Enrollment

102

Registered

2023-11-27

Start date

2023-12-06

Completion date

2025-12-22

Last updated

2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

Clinical response at Week 12

Interventions

DRUG-

DRUGMERCAPTOPURINE

DRUGFilm-Coated Tablet without JNJ-77242113

DRUGJNJ-77242113

DRUGAZATHIOPRINE

DRUGMETHOTREXATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clinical response at Week 12	—

Countries

Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026